Pieris Pharmaceuticals Inc (PIRS) News

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form EFFECT - Notice of Effectiveness

Form 425 - Prospectuses and communications, business combinations

Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations

Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™...

Form DEF 14A - Other definitive proxy statements

Form ARS - Annual Report to Security Holders

Form 425 - Prospectuses and communications, business combinations

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical...

Form 425 - Prospectuses and communications, business combinations

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report